Department of Emergency Medicine, Lampang Hospital, Muang District, Lampang, 52000, Thailand.
Center for Clinical Epidemiology and Clinical Statistics, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.
BMC Res Notes. 2023 Jul 27;16(1):158. doi: 10.1186/s13104-023-06395-y.
To examine the clinical efficacy of prophylactic metoclopramide in reducing the incidence of nausea and vomiting in emergency department (ED) patients with acute pain who were treated with intravenous tramadol.
We conducted a single-center randomized, double-blinded, placebo-controlled trial. A total of 99 ED patients presented with acute pain were recruited. Sixty-four patients were randomized, 31 patients in the treatment arm and 33 in the control arm. Overall, there were no significant differences in baseline characteristics between treatment arm and control arm. Only one patient within each arm reported having nausea symptom. No patients reported vomiting episode. There was no statistically significant difference in the proportion of patients with nausea or vomiting symptoms between the two groups (3.2% in the treatment arm vs. 3.0% in the control arm, p = 1.000). The administration of prophylactic metoclopramide may not provide additional benefit in reducing the occurrence of nausea and/or vomiting episode in ED patients with acute pain treated with intravenous tramadol. Trial registration Randomized clinical trial TCTR20220525001; registration date: 21 October 2021. Retrospectively registered.
观察预防性应用甲氧氯普胺对接受静脉注射曲马多治疗的急诊科急性疼痛患者恶心和呕吐发生率的影响。
我们进行了一项单中心、随机、双盲、安慰剂对照试验。共招募了 99 名急诊科急性疼痛患者。64 名患者被随机分配到治疗组和对照组，每组 31 名和 33 名患者。两组患者的基线特征总体无显著差异。每组各有 1 名患者报告出现恶心症状。没有患者报告呕吐发作。两组患者恶心或呕吐症状的比例无统计学差异（治疗组 3.2%，对照组 3.0%，p=1.000）。预防性应用甲氧氯普胺可能不能为接受静脉注射曲马多治疗的急诊科急性疼痛患者提供额外益处，以减少恶心和/或呕吐发作的发生。试验注册 随机临床试验 TCTR20220525001；注册日期：2021 年 10 月 21 日。回顾性注册。
